Skip to main content
. 2021 Oct 15;12(2):708–722. doi: 10.1016/j.apsb.2021.10.005

Figure 2.

Figure 2

AGEs induce alterations of key ferroptosis-associated molecules. (A) AGE-induced time-dependent ferritin expression, assessed using Western blotting (n = 3 per group). (B) AGE-induced expression of ferritin, assessed using Western blotting (n = 4 per group). (C) Labile iron levels in AGE-treated ECTs, assessed using an Iron Colorimetric Assay Kit (n = 4 per group). (D) AGE-induced expression of SLC7A11, assessed using Western blotting (n = 4 per group). (E) and (F) Alterations of GSH and GSH/GSSG levels, assessed using the Glutathione Fluorometric Assay Kit (n = 5 per group). Data are presented as the normalized mean ± SD (to control) or mean ± SD. AGEs, advanced glycation end-products; ECT, engineered cardiac tissue; GSH, glutathione; GSSG, oxidized glutathione; SLC7A11, solute carrier family 7 member 11.